Strong initial demand for Amgen and Novartis' new preventive migraine therapy Aimovig has reinforced expectations of blockbuster sales — for one analyst at least.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,